Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.56 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18550085 | 0.89 | HTR2C (0.53) | HTR2CPRMT5MAOBWDR5 | |
| SCHEMBL18549919 | 0.89 | DHFR (0.50) | HTR2CBTKMAOB | |
| SCHEMBL18550285 | 0.88 | HTR2C (0.52) | HTR2CPRMT5MAOB | |
| SCHEMBL18563771 | 0.85 | BTK (0.49) | HTR2CBTKCHRM4CHRM5CHRM1 | |
| SCHEMBL12490852 | 0.84 | HTR2C (0.78) | HTR2CCHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL18549940 | 0.83 | HTR2C (0.47) | HTR2CBTKTNKS2CYP3A4 | |
| SCHEMBL18549938 | 0.82 | BTK (0.49) | HTR2CBTKPRMT5CYP3A4WDR5 | |
| Hydrochloric Acid SCHEMBL6298979 | 0.82 | HTR2C (0.76) | HTR2CCHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL18550034 | 0.80 | BTK (0.49) | HTR2CBTKPRMT5WDR5MCHR1 | |
| SCHEMBL18563767 | 0.79 | HTR2C (0.43) | HTR2CBTKCHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368107-B | Fused heterocyclic compounds as S1P modulators | 艾伯维公司 | 2021-11-26 | — | — | CN | disclosed |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-11 | — | — | US | disclosed |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-11 | — | — | US | disclosed |
| EP-3341369-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017036978-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | ABBVIE INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | S1PR1, S1PR2, S1PR3 | HTR2C 835/4885BTK 2193/4885CHRM4 1900/4885 |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | S1PR1, S1PR2, S1PR3 | HTR2C 835/4885BTK 2193/4885CHRM4 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.